Reaction

Haemorrhage Urinary Tract reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,507 reports · 63 co-occurring drugs

As of the last recalculation, Haemorrhage Urinary Tract appears in 2,507 FAERS reports alongside 63 co-occurring drug terms. The strongest observed disproportionality signal is RIVAROXABAN (PRR 14.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Rivaroxaban	327	14.8	14.9
Prasugrel Hydrochloride	18	14.8	14.8
Brinzolamide	12	11.5	11.5
Abiraterone	18	11.0	11.1
Bicalutamide	20	11.0	11.0
Ganciclovir	13	10.6	10.6
Enzalutamide	73	10.6	10.6
Dutasteride	10	10.2	10.3
Ganciclovir Sodium	13	10.2	10.3
Busulfan	19	10.1	10.1
Ticagrelor	38	10.0	10.0
Felodipine Extended-Release Tablets	13	9.5	9.5
Felodipine	13	9.5	9.5
Sotalol Hydrochloride	18	9.0	9.1
Basiliximab	12	8.5	8.5
Abiraterone Acetate	38	7.8	7.8
Finasteride	55	7.7	7.7
Leuprolide Acetate	70	7.7	7.7
Acalabrutinib	11	7.6	7.6
Dabigatran Etexilate	68	7.4	7.5
Dabigatran Etexilate Mesylate	59	6.9	6.9
Goserelin	10	6.2	6.2
Fesoterodine Fumarate	8	6.1	6.1
Gemfibrozil	11	6.0	6.0
Dronedarone	7	5.7	5.7
Ibrutinib	54	5.7	5.7
Terazosin Hydrochloride	6	5.6	5.6
Warfarin	82	5.5	5.5
Melphalan	15	5.5	5.5
Clopidogrel	125	5.5	5.5
Warfarin Sodium	29	5.2	5.2
Clopidogrel Bisulfate	63	5.2	5.2
Brimonidine Tartrate	11	5.1	5.1
Axitinib	12	5.1	5.1
Regorafenib	7	5.0	5.0
Melphalan Hydrochloride	15	5.0	5.0
Alteplase	9	5.0	5.0
Azacitidine For	10	4.6	4.6
Sunitinib Malate	21	4.5	4.5
Relugolix	12	4.2	4.2
Vibegron	4	4.1	4.1
Emicizumab	6	4.0	4.0
Pazopanib Hydrochloride	13	4.0	4.0
Oxybutynin	14	4.0	4.0
Icosapent Ethyl	4	3.9	3.9
Mirabegron	18	3.9	3.9
Tiotropium Bromide Inhalation Spray	5	3.7	3.7
Azacitidine	13	3.7	3.7
Riociguat	14	3.6	3.6
Eculizumab	23	3.5	3.5
Apalutamide	5	3.5	3.5
Romiplostim	6	3.3	3.3
Eltrombopag Olamine	9	3.2	3.2
Vortioxetine	6	2.9	2.9
Ruxolitinib	25	2.9	2.9
Canagliflozin	10	2.8	2.8
Suvorexant	4	2.6	2.6
Venetoclax	18	2.4	2.4
Budesonide, Glycopyrrolate, And Formoterol Fumarate	3	2.4	2.4
Trifluridine And Tipiracil	3	2.3	2.3
Alirocumab	7	2.3	2.3
Ofatumumab	9	2.3	2.3
Sacubitril And Valsartan	25	1.8	1.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.